Pentixapharm Holding AG Completes Rights Offering

Pentixapharm Holding AG has successfully completed its rights offering, achieving gross issue proceeds of EUR 16.8 million, including oversubscription. Conducted as part of a capital increase announced earlier this month, the rights offering involved the issuance of 9,096,771 new shares, representing 82.5% of the planned volume. Net proceeds will finance critical stages of the PANDA Phase 3 study and support expansion into the U.S. market.

The company now offers 1,923,441 unsubscribed new shares to institutional investors via private placement until July 28, 2026. Priced at EUR 1.85 per share, this initiative aims to strengthen Pentixapharm's manufacturing infrastructure and prepare for clinical advancements, bolstering potential future commercialization efforts.